[ad_1]
Helsinki, August 3, 2021 /PRNewswire/ – Nanoform, an innovative nanoparticle drug support company, announced that it can now conduct a proof-of-concept study for Boehringer Ingelheim to evaluate the added value of Nanoform’s award-winning CESS® Technology can help its drug development projects.
The two parties have been implemented Master Service Agreement (MSA) initiated a project in the field of early preclinical development to solve the increasingly serious challenge of poor bioavailability and solubility of new drug candidates-the main reason for the failure of drug development.
Christian Jones, CCO of Nanoform, commented: “The wider adoption of the latest technological innovations is essential to address the low success rate of new drug candidates in the pharmaceutical sector. We are pleased to work with Boehringer Ingelheim to evaluate our proprietary CESS® The platform can help more new therapies reach patients who need them. This is the first step we hope to establish a long-term and fruitful partnership between our companies. “
For more information, please contact:
Peter Hänninen, General Counsel
peter.hanninen@nanoform.com / +358 50 353 0408
For investor relations inquiries, please contact:
Henry von Brielle, Chief Investment Officer…
The full story on Benzinga.com
[ad_2]
Source link
